135 related articles for article (PubMed ID: 7746194)
1. Support for trials of promising medications through the Pharmaceutical Benefits Scheme.
Bell KD
Med J Aust; 1995 Apr; 162(8):447; author reply 447-8. PubMed ID: 7746194
[No Abstract] [Full Text] [Related]
2. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
Glasziou PP
Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
[TBL] [Abstract][Full Text] [Related]
3. Support for trials of promising medications through the Pharmaceutical Benefits Scheme.
Flecknoe-Brown SC
Med J Aust; 1995 Apr; 162(8):447. PubMed ID: 7746193
[No Abstract] [Full Text] [Related]
4. Costing drug development.
Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
[No Abstract] [Full Text] [Related]
5. New estimates of drug development costs.
Frank RG
J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
[No Abstract] [Full Text] [Related]
6. Drugs with breakthrough status charm investors.
Senior M
Nat Biotechnol; 2013 Nov; 31(11):945-7. PubMed ID: 24213748
[No Abstract] [Full Text] [Related]
7. Drug pipeline: 3Q15.
DeFrancesco L
Nat Biotechnol; 2015 Nov; 33(11):1126. PubMed ID: 26544135
[No Abstract] [Full Text] [Related]
8. [Development of new drugs is too expensive].
Andreasen J
Ugeskr Laeger; 2003 May; 165(19):1959-60. PubMed ID: 12795066
[No Abstract] [Full Text] [Related]
9. Ethical and financial considerations in third-party support of investigational cancer therapies.
Young FE
Cancer; 1993 Nov; 72(9 Suppl):2854-8. PubMed ID: 8402519
[TBL] [Abstract][Full Text] [Related]
10. Barriers to participation in industry-sponsored clinical trials in pediatric type 2 diabetes.
Farrell R; Bethin K; Klingensmith G; Tamborlane WV; Gubitosi-Klug R
Pediatr Diabetes; 2017 Nov; 18(7):574-578. PubMed ID: 27807915
[TBL] [Abstract][Full Text] [Related]
11. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
Meron D
Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
[No Abstract] [Full Text] [Related]
12. Improving R&D productivity.
Smietana K; Ekstrom L; Jeffery B; Møller M
Nat Rev Drug Discov; 2015 Jul; 14(7):455-6. PubMed ID: 26065405
[No Abstract] [Full Text] [Related]
13. Sources of bias in the economic analysis of new drugs.
Rakatansky H
JAMA; 2000 Mar; 283(11):1424. PubMed ID: 10732928
[No Abstract] [Full Text] [Related]
14. Sources of bias in the economic analysis of new drugs.
Prendergast MM
JAMA; 2000 Mar; 283(11):1424. PubMed ID: 10732927
[No Abstract] [Full Text] [Related]
15. Sources of bias in the economic analysis of new drugs.
Le Pen C
JAMA; 2000 Mar; 283(11):1423-4. PubMed ID: 10732926
[No Abstract] [Full Text] [Related]
16. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
17. Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else.
Dalton A
Aust Health Rev; 2001; 24(2):7-14. PubMed ID: 11496474
[No Abstract] [Full Text] [Related]
18. Research and development costs for drugs.
Riggs TL
Lancet; 2004 Jan; 363(9404):184. PubMed ID: 14738789
[No Abstract] [Full Text] [Related]
19. [French Health Authority guide].
Bouvenot G; Dubernard JM; Rochaix L
Therapie; 2012; 67(5):407. PubMed ID: 23241249
[No Abstract] [Full Text] [Related]
20. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
[Next] [New Search]
